Company intelligence / Profile preview

Beijing Bokangjian Gene Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Beijing Bokangjian Gene Technology is a clinical-stage biotechnology company focused on the development of gene therapies for rare and genetic diseases. The company leverages its proprietary Adeno-Associated Virus (AAV) vector platform to create long-lasting treatments for conditions such as hemophilia. Its lead program, BKJ-001, is an AAV-based gene therapy for Hemophilia B that has entered clinical evaluation in China. Beyond hematology, the company is exploring gene therapy applications in other therapeutic areas involving monogenic disorders. Bokangjian Gene is headquartered in Beijing and operates integrated R&D and manufacturing facilities to support its clinical pipeline.

Therapeutic areas: Hematology
Modalities: Gene therapyAAV vector
Industry: Biotech

Beyond the preview

Go deeper on Beijing Bokangjian Gene Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Bokangjian Gene Technology.

Explore the full profile